Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of “Moderate Buy” by Analysts

Posted by Brian Himes on Sep 8th, 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $98.4167.

ARWR has been the subject of several research analyst reports. Piper Sandler reiterated an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Royal Bank Of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. B. Riley Financial increased their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. Finally, Leerink Partners upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th.

Check Out Our Latest Stock Report on Arrowhead Pharmaceuticals

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Michael Perry sold 11,600 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adeoye Olukotun sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Carolina Wealth Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. First Horizon Corp increased its position in Arrowhead Pharmaceuticals by 36.2% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 174 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Arrowhead Pharmaceuticals by 1.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock worth $737,000 after purchasing an additional 178 shares during the last quarter. Optiver Holding B.V. raised its stake in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 248 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $86.34 on Thursday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a one year low of $27.10 and a one year high of $95.49. The company’s fifty day moving average price is $84.23 and its 200-day moving average price is $74.55. The company has a market capitalization of $12.16 billion, a price-to-earnings ratio of -38.37 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company’s quarterly revenue was up 171.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.26) EPS. Sell-side analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.